Therabene Appoints Dr. Oscar Kashala as CMO to Advance Protein Degrader Pipeline for Hard-to-Treat Cancers
核心洞察
Therabene Inc. (搜索) has appointed Dr. Oscar L. Kashala as Chief Medical Officer and Executive Vice President of Global Clinical Development to accelerate its oncology drug pipeline.
Dr. Kashala brings over 30 years of leadership experience in oncology research, translational medicine, and global biopharmaceutical development across academia and industry.
The appointment positions Therabene to advance its lead programs TB-003B and TB-008 targeting aggressive cancers including triple-negative breast cancer (搜索) and pancreatic cancer (搜索).
Therabene Inc. (搜索), a preclinical-stage biotechnology company developing next-generation small-molecule protein degraders, has appointed Oscar L. Kashala, MD, PhD, DSc, as Chief Medical Officer and Executive Vice President of Global Clinical Development, effective immediately. The strategic appointment aims to accelerate the company's oncology drug pipeline and global clinical strategy as it prepares to advance its degrader-based therapies into clinical studies.
Leadership Expertise in Oncology Development
Dr. Kashala brings over 30 years of leadership in oncology research, translational medicine, and global biopharmaceutical development. His expertise spans the full spectrum of drug development from discovery through clinical trials, regulatory approval, and commercialization, gained through senior roles across academia, hospitals, government, and the pharmaceutical industry.
"Oscar's deep clinical expertise and success in bringing oncology assets through the clinic make him an ideal addition to our leadership team," said Dr. Mario DiPaola, Founder and Chief Executive Officer of Therabene Inc. (搜索) "His guidance will be instrumental as we advance our degrader-based pipeline into clinical studies."
Zoser Mohamed, President of Therabene Inc. (搜索), added: "We're thrilled to welcome Dr. Kashala. His strategic insight, regulatory knowledge, and mentorship experience will be vital as we build Therabene's global development capabilities and clinical trial infrastructure."
Clinical Development Strategy and Pipeline Focus
In his new role, Dr. Kashala will oversee Therabene's global clinical development strategy, lead regulatory and translational initiatives, and guide the design and execution of clinical trials across the company's pipeline. Therabene's lead programs—TB-003B and TB-008—are aimed at treating cancers with significant unmet need, including triple-negative breast cancer (搜索), ovarian cancer (搜索), non-small cell lung cancer (搜索), and pancreatic cancer (搜索).
"I am honored to join Therabene at such a transformative moment," said Dr. Kashala. "Therabene's commitment to scientific excellence and its innovative degrader technology platform offer a powerful opportunity to reshape the therapeutic landscape for patients battling aggressive cancers."
Academic and Research Background
Dr. Kashala earned his MD from the University of Kinshasa Medical School and completed advanced training in oncology and pathology through a collaborative program involving the University of Kinshasa, University of Lausanne, and University of Geneva. He later received a Doctor of Science degree through a joint program with Harvard University and the Massachusetts Institute of Technology.
As a widely published physician-scientist, Dr. Kashala has authored more than 50 peer-reviewed publications in oncology, immunology, and molecular therapeutics. He has received numerous accolades for his contributions to medical science and global health.
Protein Degradation Technology Platform
Therabene Inc. (搜索) is developing first-in-class small-molecule degraders that harness the power of targeted protein degradation to treat aggressive and treatment-resistant cancers. The company leverages deep medicinal chemistry expertise and maintains a robust pipeline of rationally designed inhibitors and degraders targeting kinases (搜索), with a commitment to delivering transformative therapies that improve survival and quality of life for patients with difficult-to-treat malignancies.